Home > Press > Patent for the Novel Cancer Therapies – Ceramide Nanoliposomes
 |
Abstract:
KN is pleased to announce that Penn State has been awarded a US Patent (8,747,891) for a highly unique cancer therapy. KN holds an exclusive license to this technology which builds on the work of Dr. Mark Kester of the University of Virginia. The inventing team includes: Mark Kester, Sriram Shanmugavelandy, and Todd Fox.
Patent for the Novel Cancer Therapies – Ceramide Nanoliposomes
State College, PA | Posted on March 4th, 2015This patent describes how Ceramide nano-scale liposomes can be loaded with a range of anti-cancer compounds and create a combination therapy that benefits from the therapeutic activity of both the Ceramide and the anti-cancer compound. Further, both are delivered in a nano-liposome which improves the delivery of the compounds by targeting the materials to tumors and by extending the time of biological activity (or therapeutic half-life).
Keystone Nano has conducted extensive preclinical testing on Ceramide Nanoliposomes and has submitted a Pre IND package to the US FDA. Keystone anticipates moving the Ceramide Nanoliposome program into human clinical testing in the near term. Keystone Nano's corporate partners have also contributed key support to the advancement of the technology.
Based in State College, Keystone Nano is working at the interface between nanotechnology and the life sciences and has licensed intellectual property around nanoparticles from Penn State University and is further developing this technology. The company is working to commercialize NanoJacket products and Nanoliposomes for a variety of medical applications.
####
For more information, please click here
Contacts:
Jeff Davidson, CEO
814-466-5080
Dr. Mylisa Parette
Research Manager
814-237-4657
Copyright © Keystone Nano
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Bookmark:
| Related News Press |
News and information
Sensors innovations for smart lithium-based batteries: advancements, opportunities, and potential challenges August 8th, 2025
Deciphering local microstrain-induced optimization of asymmetric Fe single atomic sites for efficient oxygen reduction August 8th, 2025
Lab to industry: InSe wafer-scale breakthrough for future electronics August 8th, 2025
New imaging approach transforms study of bacterial biofilms August 8th, 2025
Cancer
New molecular technology targets tumors and simultaneously silences two ‘undruggable’ cancer genes August 8th, 2025
Ben-Gurion University of the Negev researchers several steps closer to harnessing patient's own T-cells to fight off cancer June 6th, 2025
Nanomedicine
New molecular technology targets tumors and simultaneously silences two ‘undruggable’ cancer genes August 8th, 2025
New imaging approach transforms study of bacterial biofilms August 8th, 2025
Cambridge chemists discover simple way to build bigger molecules – one carbon at a time June 6th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Announcements
Sensors innovations for smart lithium-based batteries: advancements, opportunities, and potential challenges August 8th, 2025
Deciphering local microstrain-induced optimization of asymmetric Fe single atomic sites for efficient oxygen reduction August 8th, 2025
Japan launches fully domestically produced quantum computer: Expo visitors to experience quantum computing firsthand August 8th, 2025
ICFO researchers overcome long-standing bottleneck in single photon detection with twisted 2D materials August 8th, 2025
Patents/IP/Tech Transfer/Licensing
Getting drugs across the blood-brain barrier using nanoparticles March 3rd, 2023
Metasurfaces control polarized light at will: New research unlocks the hidden potential of metasurfaces August 13th, 2021
Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||